Long-term remissions of young patients with high-risk follicular lymphoma after first-line autologous stem cell transplantation : Three case reports
RATIONALE: Autologous stem cell transplantation (ASCT) is not routinely recommended as first-line choice for follicular lymphoma (FL). However, we actually have observed that young patients with extremely high-risk factors benefit from ASCT. This study aims to speculate the rationality of ASCT as first-line treatment, through 3 cases and review of the literature.
PATIENT CONCERNS: 3 young-adult patients with FL received ASCT as first-line treatment.
DIAGNOSIS: All the 3 patients were no more than 30 years old and the diagnosis of FL was confirmed by histopathological and immunohistochemical evaluations. They all had multi-organ involvements, and two of them presented with a "leukemic-like" manifestation. Compared with those in the previous literatures, the 3 patients were relatively younger and had more invasive clinical features.
INTERVENTIONS: The 3 patients received combined chemotherapy plus rituximab, followed by first-line ASCT.
OUTCOMES: All the 3 patients got complete remission and minimal residual disease negativity after ASCT, The median follow-up time was 109 (97-117) months, and all of them were in remission more than 8 years after transplant.
LESSONS: Guidelines for FL are mainly based on elderly patients, but are not suitable enough for all, especially for the young FL patients. For young patients with certain high-risk FL, first-line ASCT does not go against the guidelines, and should be recommended individually.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Medicine - 99(2020), 22 vom: 29. Mai, Seite e20395 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lyu, Rui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 06.07.2020 Date Revised 19.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000020395 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310618339 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310618339 | ||
| 003 | DE-627 | ||
| 005 | 20231225140500.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000020395 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310618339 | ||
| 035 | |a (NLM)32481428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lyu, Rui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term remissions of young patients with high-risk follicular lymphoma after first-line autologous stem cell transplantation |b Three case reports |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2020 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a RATIONALE: Autologous stem cell transplantation (ASCT) is not routinely recommended as first-line choice for follicular lymphoma (FL). However, we actually have observed that young patients with extremely high-risk factors benefit from ASCT. This study aims to speculate the rationality of ASCT as first-line treatment, through 3 cases and review of the literature | ||
| 520 | |a PATIENT CONCERNS: 3 young-adult patients with FL received ASCT as first-line treatment | ||
| 520 | |a DIAGNOSIS: All the 3 patients were no more than 30 years old and the diagnosis of FL was confirmed by histopathological and immunohistochemical evaluations. They all had multi-organ involvements, and two of them presented with a "leukemic-like" manifestation. Compared with those in the previous literatures, the 3 patients were relatively younger and had more invasive clinical features | ||
| 520 | |a INTERVENTIONS: The 3 patients received combined chemotherapy plus rituximab, followed by first-line ASCT | ||
| 520 | |a OUTCOMES: All the 3 patients got complete remission and minimal residual disease negativity after ASCT, The median follow-up time was 109 (97-117) months, and all of them were in remission more than 8 years after transplant | ||
| 520 | |a LESSONS: Guidelines for FL are mainly based on elderly patients, but are not suitable enough for all, especially for the young FL patients. For young patients with certain high-risk FL, first-line ASCT does not go against the guidelines, and should be recommended individually | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Wang, Tingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Dehui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Shuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wenyang |e verfasserin |4 aut | |
| 700 | 1 | |a An, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zengjun |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Lugui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 99(2020), 22 vom: 29. Mai, Seite e20395 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2020 |g number:22 |g day:29 |g month:05 |g pages:e20395 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000020395 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2020 |e 22 |b 29 |c 05 |h e20395 | ||